Business Wire

Belgian Grower Tomerel Increases Light Levels, Decreases Energy Costs Through Fluence LED Retrofit

12.5.2022 15:00:00 EEST | Business Wire | Press release

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its partnership with Tomerel, a tomato grower located in Antwerp, Belgium. Together, the companies retrofitted half of Tomerel’s glasshouse from high-pressure sodium (HPS) fixtures to LEDs, resulting in a 40% increase in light levels while decreasing energy input by 5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005116/en/

Tomerel is a multi-generational family farm led by CEO and co-owner Jelle de Ryck—son of founders Els and Eric. Tomerel specializes in glasshouse-grown tomatoes, with a particular focus on cherry tomatoes on the vine. Like many growers in the region, Jelle de Ryck scaled his family’s facility using supplemental HPS fixtures. However, when Jelle sought to maximize the glasshouse’s light output and energy consumption, he turned to Fluence’s advanced LED technology.

“When we set out to identify a partner to assist with our lighting retrofit, we weren’t just looking for lights—we wanted a team that could strategize with us from installation through harvesting. Fluence provided that service and more,” said Jelle.

After installing Fluence’s VYPR 3p top light solution, what were once critical limitations to the farm’s lighting strategy became opportunities to boost yields and reduce energy costs. Traditional HPS fixtures produce excess heat and feature inflexible spectral options. Fluence LEDs, however, run cooler and use a more efficient spectrum. With exploding energy prices in the region, the lightened load on the glasshouse’s HVAC system, in combination with the LEDs’ overall more efficient energy usage, enabled Tomerel to cut its electricity usage while increasing light levels.

“Fluence’s technology drove success for us in multiple ways. The electricity efficiencies enabled us to sell 25% more energy back to the grid and also reduced our gas consumption by 5%. The plants are also thriving under LEDs. We’re seeing improved quality and production throughout the winter months, increases in stem density and improved translocation of sugars throughout the night,” Jelle added.

In close coordination with Fluence’s technical team, Tomerel implemented a PhysioSpec™ DUAL R9B spectral strategy to accommodate plant efficacy. This strategy enabled Tomerel to decrease energy input by 5% even while increasing the amount of light by 40%, ensuring stronger cultivation conditions for Tomerel’s tomato crop. As a result, Tomerel also increased its yield by more than 5% despite the facility receiving 5% less natural light over the winter season. Tomerel also saw an increase in overall fruit weight following the retrofit.

“It is fascinating to see growers like Tomerel make innovative, smart cultivation decisions regarding energy usage,” said Timo Bongartz, general manager for Europe, the Middle East and Africa for Fluence. “The Tomerel team is saving energy wherever possible and also optimizing their facility in such a way to enable them to sell energy back to the grid. And all that without sacrificing plant quality. Fluence is delighted to support Tomerel in running a future-proof glasshouse.”

With Fluence’s technology, the Tomerel team sold 25% more of the glasshouse’s electricity produced by co-generation back to the grid during peak energy prices and saved 5% of its total gas consumption.

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence
Emma Chase
pr@fluencebioengineering.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 16:00:00 EEST | Press release

Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is ex

vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release

vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye